DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Invega (Paliperidone) - Extrapyramidal Disorder - Suspected Cause - Side Effect Reports

 
 



Index of reports > Cases with Extrapyramidal Disorder (31)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Invega (Paliperidone) where reactions include extrapyramidal disorder. The selected reports were submitted to the FDA during the sample period of about a year.

 Reports 1 - 30 of 31   Next >>

Possible Invega side effects in male

Reported by a consumer/non-health professional from United States on 2012-08-06

Patient: male

Reactions: Movement Disorder, Weight Decreased, Drug Ineffective, Pain, Muscle Tightness, Neck Pain, Musculoskeletal Disorder, Adverse Event, Injury, Depression, Muscle Spasms, Back Pain, Inappropriate Schedule of Drug Administration, Dysphagia, Dystonia, Grimacing, Condition Aggravated, Abnormal Behaviour, Torticollis, Muscle Twitching, Dissociation, Suicide Attempt, Disturbance in Attention, Tardive Dyskinesia, Extrapyramidal Disorder, Gait Disturbance, Hypertension

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Risperdal Consta
    Start date: 2009-01-01

Risperdal Consta
    Dosage: ndc 050468-306
    Start date: 2010-04-07
    End date: 2011-02-02

Risperdal Consta
    Dosage: ndc 050468-306
    Indication: Schizophrenia, Paranoid Type
    Start date: 2010-04-07
    End date: 2011-02-02

Risperdal Consta
    Dosage: every 4 to 6 weeks
    Start date: 2010-01-01
    End date: 2010-01-01

Risperdal Consta
    Start date: 2010-04-01
    End date: 2010-08-01

Invega
    Administration route: Oral
    Indication: Schizophrenia, Paranoid Type
    Start date: 2008-05-01
    End date: 2009-11-01

Risperdal
    Administration route: Oral
    Indication: Schizophrenia, Paranoid Type
    Start date: 2010-07-07
    End date: 2011-02-02

Cogentin
    Administration route: Oral
    Indication: Product Used FOR Unknown Indication
    Start date: 2011-12-11

Risperdal Consta
    Indication: Major Depression
    Start date: 2010-04-01
    End date: 2010-08-01

Risperdal Consta
    Dosage: every 4 to 6 weeks
    Start date: 2010-01-01
    End date: 2010-01-01

Risperdal Consta
    Start date: 2010-05-01
    End date: 2010-10-01

Zyprexa
    Indication: Schizophrenia

Risperdal Consta
    Dosage: every 4 to 6 weeks
    Start date: 2010-01-01
    End date: 2010-01-01

Risperdal Consta
    Dosage: ndc 050468-306
    Start date: 2010-04-07
    End date: 2011-02-02

Risperdal Consta
    Indication: Bipolar Disorder
    Start date: 2009-01-01

Risperdal Consta
    Start date: 2009-01-01

Risperdal Consta
    Start date: 2010-05-01
    End date: 2010-10-01

Risperdal Consta
    Start date: 2010-05-01
    End date: 2010-10-01

Risperdal Consta
    Start date: 2010-04-01
    End date: 2010-08-01



Possible Invega side effects in 57 year old female

Reported by a physician from Korea, Republic of on 2012-07-20

Patient: 57 year old female

Reactions: Agitation, Extrapyramidal Disorder, Depressed Mood

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Risperdal
    Administration route: Oral
    Indication: Psychotic Disorder
    Start date: 2009-06-17

Invega
    Administration route: Oral

Lamictal
    Indication: Bipolar Disorder

Lamictal
    Indication: Schizoaffective Disorder

Invega
    Administration route: Oral
    Indication: Psychotic Disorder

Lamictal
    Start date: 2009-08-01

Lamictal
    Start date: 2009-08-01

Other drugs received by patient: Benztropine Mesylate; Xanax; Propranolol Hydrochloride; Wellbutrin



Possible Invega side effects in male

Reported by a consumer/non-health professional from United States on 2012-07-03

Patient: male

Reactions: Weight Decreased, Movement Disorder, Drug Ineffective, Pain, Muscle Tightness, Neck Pain, Musculoskeletal Disorder, Adverse Event, Injury, Depression, Muscle Spasms, Back Pain, Inappropriate Schedule of Drug Administration, Dysphagia, Grimacing, Dystonia, Condition Aggravated, Abnormal Behaviour, Torticollis, Muscle Twitching, Dissociation, Disturbance in Attention, Suicide Attempt, Tardive Dyskinesia, Gait Disturbance, Extrapyramidal Disorder, Hypertension

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Risperdal Consta
    Start date: 2010-05-01
    End date: 2010-10-01

Risperdal Consta
    Start date: 2009-01-01

Risperdal Consta
    Start date: 2010-04-01
    End date: 2010-08-01

Cogentin
    Administration route: Oral
    Indication: Product Used FOR Unknown Indication
    Start date: 2011-12-11

Risperdal Consta
    Indication: Bipolar Disorder
    Start date: 2009-01-01

Risperdal Consta
    Dosage: every 4 to 6 weeks
    Start date: 2010-01-01
    End date: 2010-01-01

Risperdal Consta
    Start date: 2010-04-01
    End date: 2010-08-01

Risperdal Consta
    Dosage: ndc 050468-306
    Start date: 2010-04-07
    End date: 2011-02-02

Risperdal Consta
    Dosage: every 4 to 6 weeks
    Start date: 2010-01-01
    End date: 2010-01-01

Invega
    Administration route: Oral
    Indication: Schizophrenia, Paranoid Type
    Start date: 2008-05-01
    End date: 2009-11-01

Risperdal
    Administration route: Oral
    Indication: Schizophrenia, Paranoid Type
    Start date: 2010-07-07
    End date: 2011-02-02

Zyprexa
    Indication: Schizophrenia

Risperdal Consta
    Start date: 2009-01-01

Risperdal Consta
    Start date: 2010-05-01
    End date: 2010-10-01

Risperdal Consta
    Indication: Major Depression
    Start date: 2010-04-01
    End date: 2010-08-01

Risperdal Consta
    Start date: 2010-05-01
    End date: 2010-10-01

Risperdal Consta
    Dosage: every 4 to 6 weeks
    Start date: 2010-01-01
    End date: 2010-01-01

Risperdal Consta
    Dosage: ndc 050468-306
    Start date: 2010-04-07
    End date: 2011-02-02

Risperdal Consta
    Dosage: ndc 050468-306
    Indication: Schizophrenia, Paranoid Type
    Start date: 2010-04-07
    End date: 2011-02-02



Possible Invega side effects in male

Reported by a physician from United States on 2012-06-26

Patient: male

Reactions: Weight Decreased, Movement Disorder, Drug Ineffective, Pain, Muscle Tightness, Neck Pain, Musculoskeletal Disorder, Adverse Event, Injury, Depression, Muscle Spasms, Back Pain, Inappropriate Schedule of Drug Administration, Dysphagia, Grimacing, Dystonia, Abnormal Behaviour, Condition Aggravated, Torticollis, Muscle Twitching, Dissociation, Suicide Attempt, Disturbance in Attention, Gait Disturbance, Extrapyramidal Disorder, Tardive Dyskinesia, Hypertension

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Risperdal Consta
    Start date: 2009-01-01

Risperdal Consta
    Dosage: every 4 to 6 weeks
    Start date: 2010-01-01
    End date: 2010-01-01

Risperdal
    Administration route: Oral
    Indication: Schizophrenia, Paranoid Type
    Start date: 2010-07-07
    End date: 2011-02-02

Risperdal Consta
    Dosage: ndc 050468-306
    Start date: 2010-04-07
    End date: 2011-02-02

Risperdal Consta
    Start date: 2010-04-01
    End date: 2010-08-01

Risperdal Consta
    Start date: 2009-01-01

Cogentin
    Administration route: Oral
    Indication: Product Used FOR Unknown Indication
    Start date: 2011-12-11

Risperdal Consta
    Indication: Major Depression
    Start date: 2010-04-01
    End date: 2010-08-01

Invega
    Administration route: Oral
    Indication: Schizophrenia, Paranoid Type
    Start date: 2008-05-01
    End date: 2009-11-01

Risperdal Consta
    Dosage: every 4 to 6 weeks
    Start date: 2010-01-01
    End date: 2010-01-01

Risperdal Consta
    Dosage: every 4 to 6 weeks
    Start date: 2010-01-01
    End date: 2010-01-01

Risperdal Consta
    Start date: 2010-05-01
    End date: 2010-10-01

Risperdal Consta
    Dosage: ndc 050468-306
    Indication: Schizophrenia, Paranoid Type
    Start date: 2010-04-07
    End date: 2011-02-02

Risperdal Consta
    Start date: 2010-04-01
    End date: 2010-08-01

Zyprexa
    Indication: Schizophrenia

Risperdal Consta
    Indication: Bipolar Disorder
    Start date: 2009-01-01

Risperdal Consta
    Dosage: ndc 050468-306
    Start date: 2010-04-07
    End date: 2011-02-02

Risperdal Consta
    Start date: 2010-05-01
    End date: 2010-10-01

Risperdal Consta
    Start date: 2010-05-01
    End date: 2010-10-01



Possible Invega side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-06

Patient:

Reactions: Extrapyramidal Disorder

Drug(s) suspected as cause:
Invega



Possible Invega side effects in male

Reported by a physician from United States on 2012-06-05

Patient: male

Reactions: Movement Disorder, Weight Decreased, Drug Ineffective, Pain, Muscle Tightness, Neck Pain, Musculoskeletal Disorder, Adverse Event, Depression, Injury, Muscle Spasms, Inappropriate Schedule of Drug Administration, Back Pain, Dysphagia, Dystonia, Grimacing, Condition Aggravated, Abnormal Behaviour, Torticollis, Muscle Twitching, Dissociation, Gait Disturbance, Extrapyramidal Disorder, Tardive Dyskinesia, Hypertension

Drug(s) suspected as cause:
Invega
    Administration route: Oral
    Indication: Schizophrenia, Paranoid Type
    Start date: 2008-05-01
    End date: 2009-11-01

Risperdal Consta
    Dosage: every 4 to 6 weeks
    Start date: 2010-01-01
    End date: 2010-01-01

Risperdal Consta
    Dosage: ndc 050468-306
    Start date: 2010-04-07
    End date: 2011-02-02

Risperdal Consta
    Dosage: every 4 to 6 weeks
    Start date: 2010-01-01
    End date: 2010-01-01

Risperdal Consta
    Start date: 2010-04-01
    End date: 2010-08-01

Risperdal Consta
    Start date: 2010-05-01
    End date: 2010-10-01

Risperdal
    Administration route: Oral
    Indication: Schizophrenia, Paranoid Type
    Start date: 2010-07-07
    End date: 2011-02-02

Cogentin
    Administration route: Oral
    Indication: Product Used FOR Unknown Indication
    Start date: 2011-12-11

Risperdal Consta
    Start date: 2010-05-01
    End date: 2010-10-01

Risperdal Consta
    Start date: 2009-01-01

Risperdal Consta
    Indication: Bipolar Disorder
    Start date: 2009-01-01

Risperdal Consta
    Start date: 2009-01-01

Risperdal Consta
    Start date: 2010-04-01
    End date: 2010-08-01

Risperdal Consta
    Dosage: ndc 050468-306
    Start date: 2010-04-07
    End date: 2011-02-02

Risperdal Consta
    Dosage: ndc 050468-306
    Indication: Schizophrenia, Paranoid Type
    Start date: 2010-04-07
    End date: 2011-02-02

Risperdal Consta
    Indication: Major Depression
    Start date: 2010-04-01
    End date: 2010-08-01

Risperdal Consta
    Dosage: every 4 to 6 weeks
    Start date: 2010-01-01
    End date: 2010-01-01

Risperdal Consta
    Start date: 2010-05-01
    End date: 2010-10-01

Zyprexa
    Indication: Schizophrenia



Possible Invega side effects in male

Reported by a physician from United States on 2012-05-31

Patient: male

Reactions: Movement Disorder, Weight Decreased, Drug Ineffective, Pain, Muscle Tightness, Neck Pain, Musculoskeletal Disorder, Adverse Event, Depression, Muscle Spasms, Back Pain, Inappropriate Schedule of Drug Administration, Dysphagia, Grimacing, Dystonia, Condition Aggravated, Abnormal Behaviour, Torticollis, Muscle Twitching, Dissociation, Gait Disturbance, Tardive Dyskinesia, Extrapyramidal Disorder, Hypertension

Drug(s) suspected as cause:
Risperdal Consta
    Start date: 2010-05-01
    End date: 2010-10-01

Risperdal Consta
    Start date: 2010-04-01
    End date: 2010-08-01

Risperdal Consta
    Dosage: every 4 to 6 weeks
    Start date: 2010-01-01
    End date: 2010-01-01

Risperdal
    Administration route: Oral
    Indication: Schizophrenia, Paranoid Type
    Start date: 2010-07-07
    End date: 2011-02-02

Risperdal Consta
    Start date: 2010-05-01
    End date: 2010-10-01

Invega
    Administration route: Oral
    Indication: Schizophrenia, Paranoid Type
    Start date: 2008-05-01
    End date: 2009-11-01

Risperdal Consta
    Start date: 2009-01-01

Risperdal Consta
    Dosage: every 4 to 6 weeks
    Start date: 2010-01-01
    End date: 2010-01-01

Risperdal Consta
    Dosage: ndc 050468-306
    Start date: 2010-04-07
    End date: 2011-02-02

Risperdal Consta
    Start date: 2010-04-01
    End date: 2010-08-01

Risperdal Consta
    Start date: 2009-01-01

Zyprexa
    Indication: Schizophrenia

Risperdal Consta
    Indication: Major Depression
    Start date: 2010-04-01
    End date: 2010-08-01

Risperdal Consta
    Indication: Bipolar Disorder
    Start date: 2009-01-01

Risperdal Consta
    Dosage: ndc 050468-306
    Start date: 2010-04-07
    End date: 2011-02-02

Risperdal Consta
    Start date: 2010-05-01
    End date: 2010-10-01

Cogentin
    Administration route: Oral
    Indication: Product Used FOR Unknown Indication
    Start date: 2011-12-11

Risperdal Consta
    Dosage: every 4 to 6 weeks
    Start date: 2010-01-01
    End date: 2010-01-01

Risperdal Consta
    Dosage: ndc 050468-306
    Indication: Schizophrenia, Paranoid Type
    Start date: 2010-04-07
    End date: 2011-02-02



Possible Invega side effects in male

Reported by a consumer/non-health professional from United States on 2012-05-15

Patient: male

Reactions: Weight Decreased, Movement Disorder, Drug Ineffective, Pain, Muscle Tightness, Neck Pain, Musculoskeletal Disorder, Adverse Event, Depression, Muscle Spasms, Back Pain, Inappropriate Schedule of Drug Administration, Dysphagia, Dystonia, Grimacing, Abnormal Behaviour, Condition Aggravated, Torticollis, Muscle Twitching, Dissociation, Gait Disturbance, Tardive Dyskinesia, Extrapyramidal Disorder, Hypertension

Drug(s) suspected as cause:
Risperdal Consta
    Dosage: every 4 to 6 weeks
    Start date: 2010-01-01
    End date: 2010-01-01

Risperdal Consta
    Start date: 2009-01-01

Risperdal Consta
    Indication: Major Depression
    Start date: 2010-04-01
    End date: 2010-08-01

Risperdal Consta
    Dosage: every 4 to 6 weeks
    Start date: 2010-01-01
    End date: 2010-01-01

Risperdal Consta
    Dosage: ndc 050468-306
    Start date: 2010-04-07
    End date: 2011-02-02

Invega
    Administration route: Oral
    Indication: Schizophrenia, Paranoid Type
    Start date: 2008-05-01
    End date: 2009-11-01

Risperdal Consta
    Start date: 2010-04-01
    End date: 2010-08-01

Zyprexa
    Indication: Schizophrenia

Cogentin
    Administration route: Oral
    Indication: Product Used FOR Unknown Indication
    Start date: 2011-12-11

Risperdal Consta
    Start date: 2009-01-01

Risperdal Consta
    Dosage: ndc 050468-306
    Start date: 2010-04-07
    End date: 2011-02-02

Risperdal Consta
    Dosage: ndc 050468-306
    Indication: Schizophrenia, Paranoid Type
    Start date: 2010-04-07
    End date: 2011-02-02

Risperdal Consta
    Dosage: every 4 to 6 weeks
    Start date: 2010-01-01
    End date: 2010-01-01

Risperdal Consta
    Start date: 2010-05-01
    End date: 2010-10-01

Risperdal Consta
    Indication: Bipolar Disorder
    Start date: 2009-01-01

Risperdal Consta
    Start date: 2010-05-01
    End date: 2010-10-01

Risperdal Consta
    Start date: 2010-04-01
    End date: 2010-08-01

Risperdal Consta
    Start date: 2010-05-01
    End date: 2010-10-01

Risperdal
    Administration route: Oral
    Indication: Schizophrenia, Paranoid Type
    Start date: 2010-07-07
    End date: 2011-02-02



Possible Invega side effects in male

Reported by a consumer/non-health professional from United States on 2012-04-27

Patient: male

Reactions: Weight Decreased, Movement Disorder, Drug Ineffective, Pain, Muscle Tightness, Neck Pain, Musculoskeletal Disorder, Adverse Event, Depression, Muscle Spasms, Inappropriate Schedule of Drug Administration, Back Pain, Dysphagia, Dystonia, Grimacing, Abnormal Behaviour, Condition Aggravated, Torticollis, Muscle Twitching, Dissociation, Extrapyramidal Disorder, Gait Disturbance, Tardive Dyskinesia, Hypertension

Drug(s) suspected as cause:
Risperdal Consta
    Indication: Major Depression
    Start date: 2010-04-01
    End date: 2010-08-01

Risperdal Consta
    Indication: Bipolar Disorder
    Start date: 2009-01-01

Risperdal Consta
    Dosage: ndc 050468-306
    Indication: Schizophrenia, Paranoid Type
    Start date: 2010-04-07
    End date: 2011-02-02

Invega
    Administration route: Oral
    Indication: Schizophrenia, Paranoid Type
    Start date: 2008-05-01
    End date: 2009-11-01

Zyprexa
    Indication: Schizophrenia

Risperdal Consta
    Dosage: every 4 to 6 weeks
    Start date: 2010-01-01
    End date: 2010-01-01

Risperdal Consta
    Start date: 2010-05-01
    End date: 2010-10-01

Risperdal Consta
    Dosage: every 4 to 6 weeks
    Start date: 2010-01-01
    End date: 2010-01-01

Risperdal Consta
    Start date: 2009-01-01

Risperdal Consta
    Start date: 2010-04-01
    End date: 2010-08-01

Risperdal
    Administration route: Oral
    Indication: Schizophrenia, Paranoid Type
    Start date: 2010-07-07
    End date: 2011-02-02

Cogentin
    Administration route: Oral
    Indication: Product Used FOR Unknown Indication
    Start date: 2011-12-11

Risperdal Consta
    Start date: 2010-05-01
    End date: 2010-10-01

Risperdal Consta
    Start date: 2010-04-01
    End date: 2010-08-01

Risperdal Consta
    Start date: 2009-01-01

Risperdal Consta
    Dosage: ndc 050468-306
    Start date: 2010-04-07
    End date: 2011-02-02

Risperdal Consta
    Dosage: every 4 to 6 weeks
    Start date: 2010-01-01
    End date: 2010-01-01

Risperdal Consta
    Start date: 2010-05-01
    End date: 2010-10-01

Risperdal Consta
    Dosage: ndc 050468-306
    Start date: 2010-04-07
    End date: 2011-02-02



Possible Invega side effects in 20 year old male

Reported by a physician from United States on 2012-04-06

Patient: 20 year old male

Reactions: Extrapyramidal Disorder

Drug(s) suspected as cause:
Invega



Possible Invega side effects in male

Reported by a consumer/non-health professional from United States on 2012-04-05

Patient: male

Reactions: Movement Disorder, Weight Decreased, Drug Ineffective, Pain, Muscle Tightness, Neck Pain, Musculoskeletal Disorder, Adverse Event, Depression, Muscle Spasms, Back Pain, Inappropriate Schedule of Drug Administration, Dysphagia, Grimacing, Dystonia, Condition Aggravated, Abnormal Behaviour, Torticollis, Muscle Twitching, Dissociation, Gait Disturbance, Extrapyramidal Disorder, Tardive Dyskinesia, Hypertension

Drug(s) suspected as cause:
Risperdal Consta
    Start date: 2010-04-01
    End date: 2010-08-01

Risperdal Consta
    Start date: 2009-01-01

Risperdal Consta
    Dosage: every 4 to 6 weeks
    Indication: Bipolar Disorder
    Start date: 2010-01-01
    End date: 2010-01-01

Risperdal Consta
    Start date: 2010-04-01
    End date: 2010-08-01

Risperdal Consta
    Dosage: ndc 050468-306
    Start date: 2010-04-07
    End date: 2011-02-02

Risperdal Consta
    Start date: 2010-05-01
    End date: 2010-10-01

Risperdal Consta
    Dosage: every 4 to 6 weeks
    Indication: Schizophrenia, Paranoid Type
    Start date: 2010-01-01
    End date: 2010-01-01

Risperdal Consta
    Start date: 2009-01-01

Risperdal Consta
    Dosage: ndc 050468-306
    Start date: 2010-04-07
    End date: 2011-02-02

Risperdal Consta
    Start date: 2010-04-01
    End date: 2010-08-01

Risperdal
    Administration route: Oral
    Indication: Schizophrenia, Paranoid Type
    Start date: 2010-07-07
    End date: 2011-02-02

Risperdal Consta
    Dosage: ndc 050468-306
    Start date: 2010-04-07
    End date: 2011-02-02

Risperdal Consta
    Start date: 2009-01-01

Invega
    Administration route: Oral
    Indication: Schizophrenia, Paranoid Type
    Start date: 2008-05-01
    End date: 2009-11-01

Risperdal Consta
    Dosage: every 4 to 6 weeks
    Indication: Major Depression
    Start date: 2010-01-01
    End date: 2010-01-01

Risperdal Consta
    Start date: 2010-05-01
    End date: 2010-10-01

Zyprexa
    Indication: Schizophrenia

Cogentin
    Administration route: Oral
    Indication: Product Used FOR Unknown Indication
    Start date: 2011-12-11

Risperdal Consta
    Start date: 2010-05-01
    End date: 2010-10-01



Possible Invega side effects in 55 year old male

Reported by a physician from United States on 2012-03-30

Patient: 55 year old male

Reactions: Extrapyramidal Disorder, Repetitive Speech

Drug(s) suspected as cause:
Invega
    Administration route: Oral
    Start date: 2012-01-01
    End date: 2012-01-01

Invega
    Administration route: Oral
    Indication: Schizoaffective Disorder
    Start date: 2012-01-01
    End date: 2012-01-01

Invega
    Administration route: Oral
    Start date: 2012-01-01
    End date: 2012-01-01

Other drugs received by patient: Metformin HCL; Depakote; Klonopin



Possible Invega side effects in female

Reported by a physician from Turkey on 2012-03-23

Patient: female

Reactions: Extrapyramidal Disorder, Parkinsonism

Adverse event resulted in: death

Drug(s) suspected as cause:
Amisulpride
    Indication: Product Used FOR Unknown Indication

Invega
    Administration route: Oral
    Indication: Schizophrenia
    End date: 2012-02-28

Valproate Sodium
    Indication: Product Used FOR Unknown Indication



Possible Invega side effects in 28 year old male

Reported by a consumer/non-health professional from Japan on 2012-03-21

Patient: 28 year old male

Reactions: Phobia, Cluttering, Hallucination, Auditory, Delusion, Myalgia, Weight Increased, Fatigue, Anger, Drug Effect Decreased, Dystonia, Blepharospasm, Hypoaesthesia, Convulsion, Aggression, Irritability, Panic Attack, Insomnia, Ocular Hyperaemia, Nervous System Disorder, Tardive Dyskinesia, Withdrawal Syndrome, Extrapyramidal Disorder

Drug(s) suspected as cause:
Risperdal
    Administration route: Oral

Chlorpromazine HCL
    Indication: Product Used FOR Unknown Indication

Risperdal
    Administration route: Oral
    Indication: Schizophrenia
    End date: 2011-02-15

Risperdal
    Administration route: Oral

Invega
    Administration route: Oral

Risperdal
    Administration route: Oral

Invega
    Administration route: Oral
    Start date: 2011-02-19

Risperdal
    Administration route: Oral
    Start date: 2011-02-21

Chlorpromazine HCL

Invega
    Administration route: Oral
    Indication: Schizophrenia

Invega
    Administration route: Oral

Invega
    Administration route: Oral
    Start date: 2011-02-16

Risperdal
    Administration route: Oral

Risperdal
    Administration route: Oral

Other drugs received by patient: Clonazepam; Artane; Dogmatyl; Tegretol



Possible Invega side effects in 7 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-03-15

Patient: 7 year old female

Reactions: Catatonia, Extrapyramidal Disorder, Staring, Hypersomnia, Convulsion

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Invega



Possible Invega side effects in male

Reported by a physician from United States on 2012-02-03

Patient: male, weighing 78.9 kg (173.6 pounds)

Reactions: Extrapyramidal Disorder, Treatment Noncompliance

Drug(s) suspected as cause:
Invega Sustenna
    Indication: Product Used FOR Unknown Indication

Invega
    Administration route: Oral
    Indication: Psychotic Disorder
    Start date: 2011-09-01
    End date: 2011-11-28



Possible Invega side effects in female

Reported by a physician from Japan on 2011-12-19

Patient: female, weighing 50.0 kg (110.0 pounds)

Reactions: Femur Fracture, Extrapyramidal Disorder, Fall

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Invega
    Administration route: Oral
    Indication: Schizophrenia, Paranoid Type
    Start date: 2011-09-22

Invega
    Administration route: Oral
    Start date: 2011-07-25
    End date: 2011-09-21

Other drugs received by patient: Rozerem; Akineton; Nitrazepam; Rabeprazole Sodium



Possible Invega side effects in 57 year old female

Reported by a physician from Korea, Republic of on 2011-12-12

Patient: 57 year old female

Reactions: Agitation, Extrapyramidal Disorder, Depressed Mood

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Invega
    Administration route: Oral

Lamictal
    Start date: 2009-08-01

Risperdal
    Administration route: Oral
    Indication: Psychotic Disorder
    Start date: 2009-06-17

Lamictal
    Start date: 2009-08-01

Lamictal
    Indication: Bipolar Disorder

Invega
    Administration route: Oral
    Indication: Psychotic Disorder

Lamictal
    Indication: Schizoaffective Disorder

Other drugs received by patient: Propranolol HCL; Benztropine Mesylate; Wellbutrin; Xanax



Possible Invega side effects in male

Reported by a physician from United States on 2011-12-09

Patient: male

Reactions: Extrapyramidal Disorder

Drug(s) suspected as cause:
Invega Sustenna
    Indication: Schizophrenia
    Start date: 2011-01-01

Invega
    Administration route: Oral

Invega
    Administration route: Oral
    Indication: Schizophrenia
    Start date: 2011-01-01
    End date: 2011-11-01

Other drugs received by patient: Cogentin



Possible Invega side effects in male

Reported by a physician from United States on 2011-11-30

Patient: male, weighing 74.8 kg (164.6 pounds)

Reactions: Akathisia, Flat Affect, Social Phobia, Nasal Congestion, Compulsions, Aggression, Dyspnoea Exertional, Illogical Thinking, Extrapyramidal Disorder

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Invega
    Administration route: Oral
    Indication: Bipolar Disorder

Invega
    Administration route: Oral
    Start date: 2009-02-01
    End date: 2011-08-24

Risperdal
    Administration route: Oral
    Indication: Bipolar Disorder
    Start date: 2011-08-24
    End date: 2011-09-29

Other drugs received by patient: Propranolol; Synthroid; Zoloft



Possible Invega side effects in female

Reported by a physician from Belgium on 2011-11-18

Patient: female

Reactions: Confusional State, Dehydration, Urinary Tract Infection, Extrapyramidal Disorder

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Invega



Possible Invega side effects in female

Reported by a physician from Japan on 2011-11-17

Patient: female, weighing 50.0 kg (110.0 pounds)

Reactions: Fracture, Extrapyramidal Disorder, Fall

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Invega
    Administration route: Oral
    Indication: Schizophrenia, Paranoid Type
    Start date: 2011-09-22

Invega
    Administration route: Oral
    Start date: 2011-07-25
    End date: 2011-09-21

Other drugs received by patient: Akineton; Rozerem; Rabeprazole Sodium; Nitrazepam



Possible Invega side effects in 28 year old male

Reported by a consumer/non-health professional from Japan on 2011-11-14

Patient: 28 year old male

Reactions: Phobia, Cluttering, Hallucination, Auditory, Delusion, Weight Increased, Myalgia, Fatigue, Anger, Blepharospasm, Dystonia, Hypoaesthesia, Aggression, Convulsion, Panic Attack, Ocular Hyperaemia, Insomnia, Nervous System Disorder, Withdrawal Syndrome, Extrapyramidal Disorder, Tardive Dyskinesia

Drug(s) suspected as cause:
Invega
    Administration route: Oral
    Indication: Schizophrenia
    Start date: 2011-02-19

Invega
    Administration route: Oral

Risperdal
    Administration route: Oral
    Start date: 2011-02-21

Risperdal
    Administration route: Oral

Invega
    Administration route: Oral

Risperdal
    Administration route: Oral

Risperdal
    Administration route: Oral

Risperdal
    Administration route: Oral
    Indication: Schizophrenia
    End date: 2011-02-15

Invega
    Administration route: Oral
    Start date: 2011-02-16

Chlorpromazine HCL
    Indication: Product Used FOR Unknown Indication

Other drugs received by patient: Tegretol; Clonazepam; Artane; Dogmatyl



Possible Invega side effects in female

Reported by a consumer/non-health professional from United States on 2011-11-02

Patient: female

Reactions: Weight Increased, Prolactinoma, Extrapyramidal Disorder, Injury

Drug(s) suspected as cause:
Invega

Other drugs received by patient: Ibuprofen; Lexapro



Possible Invega side effects in female

Reported by a health professional (non-physician/pharmacist) from United States on 2011-11-02

Patient: female

Reactions: Extrapyramidal Disorder

Drug(s) suspected as cause:
Invega



Possible Invega side effects in female

Reported by a physician from Belgium on 2011-11-02

Patient: female

Reactions: Hospitalisation, Extrapyramidal Disorder

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Invega



Possible Invega side effects in 64 year old female

Reported by a physician from Korea, Republic of on 2011-10-28

Patient: 64 year old female

Reactions: Extrapyramidal Disorder, Delusion, Psychotic Behaviour

Drug(s) suspected as cause:
Invega
    Dosage: for one month
    Administration route: Oral

Invega
    Administration route: Oral

Invega
    Administration route: Oral
    Indication: Schizophrenia



Possible Invega side effects in female

Reported by a lawyer from United States on 2011-10-25

Patient: female

Reactions: Weight Increased, Prolactinoma, Injury, Extrapyramidal Disorder

Drug(s) suspected as cause:
Invega

Other drugs received by patient: Ibuprofen; Lexapro



Possible Invega side effects in 64 year old female

Reported by a physician from Korea, Republic of on 2011-10-24

Patient: 64 year old female

Reactions: Extrapyramidal Disorder, Psychotic Behaviour, Delusion

Drug(s) suspected as cause:
Invega
    Administration route: Oral

Invega
    Administration route: Oral
    Indication: Product Used FOR Unknown Indication

Invega
    Dosage: for one month
    Administration route: Oral



Possible Invega side effects in 57 year old female

Reported by a physician from Korea, Republic of on 2011-10-24

Patient: 57 year old female

Reactions: Agitation, Extrapyramidal Disorder, Depressed Mood

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Risperdal
    Administration route: Oral
    Indication: Psychotic Disorder
    Start date: 2009-06-01

Invega
    Administration route: Oral
    Indication: Psychotic Disorder

Lamictal
    Indication: Schizoaffective Disorder

Invega
    Administration route: Oral

Lamictal
    Start date: 2009-08-01

Lamictal
    Start date: 2009-08-01

Lamictal
    Indication: Bipolar Disorder

Other drugs received by patient: Xanax; Wellbutrin



 Page 1   Next >>

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017